Point de vue actuel du traitement des epilepsies: place des nouveaux antiepileptiques? [Current viewpoints in the treatment of epilepsies: role of new antiepileptics?]

Détails

ID Serval
serval:BIB_E40CDC6B7278
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Point de vue actuel du traitement des epilepsies: place des nouveaux antiepileptiques? [Current viewpoints in the treatment of epilepsies: role of new antiepileptics?]
Périodique
Schweizerische Rundschau fur Medizin Praxis
Auteur(s)
Despland  P. A.
ISSN
1013-2058 (Print)
Statut éditorial
Publié
Date de publication
09/1995
Volume
84
Numéro
38
Pages
1036-41
Notes
English Abstract
Journal Article
Review --- Old month value: Sep 19
Résumé
Although standard anticonvulsants are effective in achieving complete seizure control in the majority of patients, an appreciable proportion (about 20 to 25%) is at least in part resistant to conventional pharmacotherapy. Efficacy of carbamazepine, phenytoin, phenobarbital and valproate is very similar. Should one drug fail because of inadequate efficacy and unacceptable adverse effects, an alternative monotherapy should be used. Surgical treatment is a possible therapeutic option for only some of these patients. The development of newer, more effective drugs, such as vigabatrin, lamotrigine, gabapentin and oxcarbazepine, for monotherapy is desirable. The search for new antiepileptic agents is reasonable in order to reduce the proportion of drug-resistant patients. The choice of conventional or new drugs should include not only expected efficacy and risk of adverse effects, but also pharmacokinetic properties and expense. Consequently, no general rule is appropriate, and each decision and recommendation for treatment should be individualized.
Mots-clé
4-Aminobutyrate Transaminase/antagonists & inhibitors Acetic Acids/therapeutic use *Amines Anticonvulsants/*therapeutic use Carbamazepine/analogs & derivatives/therapeutic use *Cyclohexanecarboxylic Acids Drug Therapy, Combination Drug Tolerance Enzyme Inhibitors/therapeutic use Epilepsy/*drug therapy Humans Triazines/therapeutic use Vigabatrin gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use
Pubmed
Création de la notice
25/01/2008 11:40
Dernière modification de la notice
20/08/2019 16:07
Données d'usage